2026-2034年全球合成大麻素市场规模、份额、趋势和成长分析报告

预计合成大麻素市场将从 2025 年的 58.8 亿美元成长到 2034 年的 336.3 亿美元，2026 年至 2034 年的复合年增长率为 21.39%。

合成大麻素市场持续稳定成长，这主要得益于对新型治疗应用的持续研究以及不断变化的监管环境。与天然大麻素不同，合成大麻素旨在精准作用于大麻素受体，为疼痛管理、神经退化性疾病和肿瘤治疗等领域提供了潜在的治疗机会。然而，滥用、毒性和无序分销等问题，以及严格的合规要求，也对市场发展产生影响。

製药公司和研究机构正致力于开发安全、标准化的合成大麻素製剂。分子建模和生物技术的进步使得设计具有标靶治疗效果且副作用最小的化合物成为可能。临床试验和专利申请数量的增加表明，基于大麻素的药物商业化进展强劲。同时，严格的品管标准的实施确保了生产的一致性和安全性。

展望未来，已开发地区对大麻素疗法的接受度不断提高，以及法规结构的逐步改善，将对市场产生正面影响。合成大麻素替代品领域也将涌现出新的机会，这些替代品能够提供稳定的剂量和扩充性。随着个人化和精准医疗的重要性日益凸显，合成大麻素有望在医疗保健领域得到更广泛的应用。生物技术创新者与製药巨头之间的策略合作将加速市场成熟。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球合成大麻素市场：依产品类型划分

• 市场分析、洞察与预测
• 高纯度合成大麻素
• 超高纯度合成大麻素

第五章：全球合成大麻素市场：依适应症划分

• 市场分析、洞察与预测
• 疼痛管理
• 噁心和呕吐
• 神经系统疾病的管理
• 其他的

第六章 全球合成大麻素市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第七章 全球合成大麻素市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Mylan NV
  • Alkem Labs
  • Noramco
  • Lygos Inc
  • Hyasynth Biologicals Inc
  • Renew Biopharma
  • CannBioRx Life Sciences
  • Ginkgo Bioworks
  • Zymergen Inc
  • Demetrix Inc

The Synthetic Cannabinoids Market size is expected to reach USD 33.63 Billion in 2034 from USD 5.88 Billion (2025) growing at a CAGR of 21.39% during 2026-2034.

The synthetic cannabinoids market is growing steadily, fueled by ongoing research into novel therapeutic applications and evolving regulatory landscapes. Unlike natural cannabinoids, synthetic variants are engineered to interact with cannabinoid receptors in precise ways, offering potential for treatments in pain management, neurodegenerative disorders, and oncology. However, the market is also shaped by strict compliance requirements due to concerns over misuse, toxicity, and unregulated distribution.

Pharmaceutical companies and research institutions are focusing on developing safe, standardized synthetic cannabinoid formulations. Advances in molecular modeling and biotechnology are enabling the design of compounds with targeted therapeutic effects while minimizing adverse reactions. Clinical trials and patent filings are increasing, indicating strong momentum toward commercialized cannabinoid-based medicines. Meanwhile, the adoption of stringent quality control standards is ensuring consistency and safety in production.

Looking forward, the market will benefit from increasing acceptance of cannabinoid therapies and progressive regulatory frameworks in developed regions. Opportunities will also emerge in synthetic alternatives to cannabis-derived products, offering consistent dosing and scalability. As personalized medicine and precision therapeutics gain prominence, synthetic cannabinoids are likely to find wider application across healthcare. Strategic partnerships between biotech innovators and pharmaceutical giants will accelerate market maturity.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• High-pure Synthetic Cannabinoid
• Ultra-pure Synthetic Cannabinoid

By Indication

• Pain Management
• Nausea/Vomiting
• Neurological Disorder Management
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Mylan NV, Alkem Labs, Noramco, Lygos Inc, Hyasynth Biologicals Inc, Renew Biopharma, CannBioRx Life Sciences, Ginkgo Bioworks, Zymergen Inc, Demetrix Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. High-pure Synthetic Cannabinoid Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Ultra-pure Synthetic Cannabinoid Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Pain Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Nausea/Vomiting Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Neurological Disorder Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SYNTHETIC CANNABINOIDS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Mylan N.V
  • 9.2.2 Alkem Labs
  • 9.2.3 Noramco
  • 9.2.4 Lygos Inc
  • 9.2.5 Hyasynth Biologicals Inc
  • 9.2.6 Renew Biopharma
  • 9.2.7 CannBioRx Life Sciences
  • 9.2.8 Ginkgo Bioworks
  • 9.2.9 Zymergen Inc
  • 9.2.10 Demetrix Inc